Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) dropped 15% during mid-day trading on Wednesday . The company traded as low as $0.99 and last traded at $1.02. Approximately 300 shares were traded during mid-day trading, a decline of 33% from the average daily volume of 448 shares. The stock had previously closed at $1.20.
Defence Therapeutics Price Performance
The stock’s 50 day moving average price is $1.36 and its 200-day moving average price is $1.66.
About Defence Therapeutics
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Featured Stories
- Five stocks we like better than Defence Therapeutics
- Financial Services Stocks Investing
- Heat Alert: Micron Just Got Named A Must-Own Stock for Q2
- With Risk Tolerance, One Size Does Not Fit All
- WD-40 Company Greases the Wheels of Growth and Profits
- How to Capture the Benefits of Dividend Increases
- How to Protect your Portfolio Against a Rising VIX
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
